Lifera has recently announced an exciting partnership with Novo Nordisk, the leading producer of insulin worldwide. Through Lifera’s subsidiary, SaudiBio, the two companies have agreed to localize insulin production in Saudi Arabia. This move is set to foster technology transfer and cultivate a skilled local biopharmaceutical workforce with aseptic production capabilities. By 2027, Saudi Arabia is poised to become the first producer of a biologic innovator insulin in the Gulf Cooperation Council (GCC) region. These efforts towards insulin manufacturing localization will not only enhance the country’s economy by growing the biopharmaceutical sector but also contribute to Saudi’s Vision 2030.
Lifera’s Mission is focused on improving Saudi Arabia’s biopharma resilience and enabling the National Biotechnology Strategy, both of which are furthered through the localization of insulin, an essential medicine, and the development of state-of-the-art biomanufacturing capacity. This significant achievement in local biopharmaceutical manufacturing has facilitated top-tier global knowledge transfer and will help train the next generation of Saudi workforce skilled in highly technical aseptic manufacturing. It is expected to create over 200 high-skilled jobs in Saudi Arabia by 2027/28, contributing to the growth of the local economy and providing valuable employment opportunities.
The partnership between Lifera and Novo Nordisk not only enhances access to affordable medications but also strengthens the nation’s healthcare supply chain. With Novo Nordisk Saudi Arabia bringing innovation closer to patients living with diabetes in the Kingdom of Saudi Arabia, the announcement of Insulin Local Manufacturing is a step towards ensuring sustainable access to innovative medication. Collaborating with NUPCO, the Local Content and General Procurement Agency (LCGPA), and other key stakeholders is crucial in improving the quality of life for people living with diabetes in the region.
Dr. Ibrahim Aljuffali, Chairman of the Lifera Board of Directors, expressed his pride in counting Novo Nordisk as a customer and the trust placed in Lifera to meet and exceed their rigorous standards. Through this partnership, Lifera is taking a significant step towards achieving its mission of localizing the manufacturing of essential medicines in Saudi Arabia and enabling the National Biotechnology Strategy by deploying state-of-the-art biomanufacturing capacity. This collaboration marks a milestone in the local biopharmaceutical industry and showcases Saudi Arabia’s commitment to advancing healthcare and technology within the region.
Overall, the agreement between Lifera and Novo Nordisk signifies a strategic move towards advancing the biopharmaceutical sector in Saudi Arabia and achieving self-sufficiency in insulin production. By localizing insulin manufacturing, the country is not only creating opportunities for economic growth and technological advancement but also improving access to essential medications for those in need. This partnership underscores the importance of collaboration and innovation in driving positive change within the healthcare industry, ultimately benefiting the people of Saudi Arabia and beyond.
